Bacterial Vaccine For Ovine Species (e.g., Sheep, Etc.) Patents (Class 424/824)
-
Patent number: 8993252Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: March 21, 2013Date of Patent: March 31, 2015Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 8173139Abstract: Populations of Salmonella in animals may be substantially reduced by treatment with a vaccine composition which has been produced by exposing whole, intact cells of a Salmonella species to irradiation with an electron beam under conditions effective to kill the cells. The electron beam irradiated cells of Salmonella are effective for stimulating protective immune responses in the animals against the Salmonella. Induction of these immune responses significantly reduces or eliminates the colonization of the animal by the Salmonella, and consequently reduces or eliminates the shedding of Salmonella in the feces of the animals.Type: GrantFiled: September 10, 2009Date of Patent: May 8, 2012Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Jackson L. McReynolds, Suresh Pillai, Palmy Rose Rajan Jesudhasan, Martha Lucia Cepeda Hernandez
-
Patent number: 7138124Abstract: The present invention provides compositions including at least two siderophore receptor polypeptides and at least two porins from a gram negative microbe, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of makino and methods of using such compositions.Type: GrantFiled: June 3, 2003Date of Patent: November 21, 2006Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Patent number: 6984381Abstract: A novel vaccine for immunizing animals against Staphylococcus aureus-induced mastitis is disclosed. The vaccine is comprised of whole killed cells of S. aureus in a dosage effective to immunize an animal against the organism, in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: July 5, 2002Date of Patent: January 10, 2006Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Albert Guidry, Celia O'Brien
-
Patent number: 6936263Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.Type: GrantFiled: August 16, 2002Date of Patent: August 30, 2005Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZWInventors: Hilde Revets, Pierre Cornelis, Patrick De Baetselier
-
Patent number: 6660262Abstract: A new and improved formulation and method for making same, for a broad spectrum antimicrobial treatment for bacterial and viral infections in cattle, horses, pigs, sheep and other domestic and non-domestic animals. More particularly, the present invention relates to a treatment which enables rapid relief of symptoms in an affected animal with a mortality of less than 1 percent by providing trace organic minerals in microgram quantities which act as nutrients for the animal. The treatment provides further nutritional requirements in the form of vitamin A, folic acid and vitamin D3 supplements, cobalt amino acid chelates and dried kelp, a source of minerals, amino acids, simple and complex carbohydrates, iodine and fiber. In addition, a bacterial innoculum consisting of Acidophilus species is introduced which would inhibit growth of pathogenic or opportunistic species of bacteria by competition for nutrients as well as providing for required vitamins as a by-product of metabolism.Type: GrantFiled: September 28, 2001Date of Patent: December 9, 2003Assignee: Bovine Health Products, Inc.Inventor: Randy R. McKinney
-
Patent number: 6534088Abstract: This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.Type: GrantFiled: April 20, 2001Date of Patent: March 18, 2003Assignee: SkyePharma Canada Inc.Inventors: Pol-Henri W. Guivarc'h, Indu Parikh, Robert A. Snow
-
Patent number: 6264952Abstract: Vaccines against facultative intracellular pathogens are disclosed. A host is vaccinated with non-viable but metabolically active agents. The non-viable agents produce immunogenic components that elicit protective host immune responses, with minimal likelihood of host infection by the vaccine agent. Living agents, either attenuated or virulent, are exposed to a dose of gamma irradiation (or other strong mutagen) that is sufficient to limit or prevent the replication of the agents within the host, but that is insufficient to stop the metabolic activities of the agent. In vitro exposure of a microbial agent to the damaging effects of gamma irradiation or of another strong mutagen induces certain stress responses in the infectious agent. These stress responses are similar to the stress responses that the virulent agent would produce within the tissues of the host.Type: GrantFiled: December 11, 1997Date of Patent: July 24, 2001Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Virginia Polytechnic Institute and State University, Board of Regents for Oklahoma State University, Cornell Research Foundation, Inc.Inventors: Frederick M. Enright, Alexander J. Winter, Gerhardt G. Schurig, John H. Wyckoff, III
-
Patent number: 6027736Abstract: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.Type: GrantFiled: July 30, 1997Date of Patent: February 22, 2000Assignee: Willmar Poultry Country, Inc.Inventors: Daryll A. Emery, Darren E. Straub, Richard Huisinga, Beth A. Carlson
-
Patent number: 6019984Abstract: Novel bacterial preparations containing one or more isolated and purified strain of a microorganism which produces one or more RTX toxins, and which strain has at least one RTX toxin which is substantially cell-associated. Methods of preparing the bacterial preparations and their use as vaccines and to produce antibodies for passive immunization are described.Type: GrantFiled: December 23, 1996Date of Patent: February 1, 2000Assignee: University of GuelphInventors: Janet MacInnes, Paul Ricciatti, Bonnie Mallard, Soren Rosendal, deceased
-
Patent number: 5955090Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.Type: GrantFiled: December 14, 1995Date of Patent: September 21, 1999Assignee: Chiron Behring GmbH & Co.Inventors: Bernhard Knapp, Klaus-Dieter Hungerer, Michael Broker, Bernd-Ulrich von Specht, Horst Domdey
-
Patent number: 5830479Abstract: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.Type: GrantFiled: February 8, 1995Date of Patent: November 3, 1998Assignee: Willmar Poultry Company, Inc.Inventors: Daryll A. Emery, Darren E. Straub, Richard Huisinga, Beth A. Carlson
-
Patent number: 5817662Abstract: Compounds and pharmaceutical compositions thereof comprise the formula:(R)j-(core moiety),including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.Type: GrantFiled: June 6, 1995Date of Patent: October 6, 1998Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Alistair J. Leigh
-
Patent number: 5637303Abstract: The present invention relates to a vaccine vector comprising a virulent corynebacterium or related organism which is incapable of expressing an active virulent factor or a non-virulent corynebacterium or related organism which synthesises an immuno protection effective amount of an antigen of a pathogenic organism and its use to stimulate a protective immune response against virulent members of this group.Type: GrantFiled: April 4, 1995Date of Patent: June 10, 1997Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Anthony J. Radford, Adrian L. M. Hodgson